Anti‐retinal Autoantibodies in Hydroxychloroquine Eye Toxicity
Objective Autoimmune retinopathy and hydroxychloroquine (HCQ)‐related retinal toxicity share many similarities, raising the possibility autoimmunity plays a role in HCQ retinopathy. The objective of this study is to determine whether patients diagnosed with HCQ retinal toxicity are more likely to ha...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | ACR Open Rheumatology |
| Online Access: | https://doi.org/10.1002/acr2.11743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832542413758922752 |
|---|---|
| author | Samuel D. Good Grazyna Adamus Michael B. Gorin Jordan Jacquez Jennifer Grossman Isao Matsuura Ashira Hasan Brian Skaggs Maureen McMahon |
| author_facet | Samuel D. Good Grazyna Adamus Michael B. Gorin Jordan Jacquez Jennifer Grossman Isao Matsuura Ashira Hasan Brian Skaggs Maureen McMahon |
| author_sort | Samuel D. Good |
| collection | DOAJ |
| description | Objective Autoimmune retinopathy and hydroxychloroquine (HCQ)‐related retinal toxicity share many similarities, raising the possibility autoimmunity plays a role in HCQ retinopathy. The objective of this study is to determine whether patients diagnosed with HCQ retinal toxicity are more likely to have circulating antiretinal autoantibodies (AAbs) compared to controls. Methods We tested plasma samples for the presence of anti‐retinal AAbs by immunoblotting in 270 patients with systemic lupus erythematosus (SLE) receiving HCQ. We then evaluated for the presence of HCQ retinal toxicity and other baseline risk factors for HCQ toxicity through chart review. Frequency of specific anti‐retinal AAbs in patients with HCQ retinal toxicity was compared to those with no retinal toxicity via multivariate logistic regression. Results Patients with HCQ retinal toxicity had a higher likelihood of testing positive for anti‐arrestin AAbs (60.7% vs 30.6%, P = 0.001) and anti–pyruvate kinase M2 AAbs (46.4% vs 28.1%, P = 0.05). Patients with HCQ eye toxicity also had a higher number of total anti‐retinal AAbs (mean 3.0 ± 2.40 vs 2.04 ± 1.7, P = 0.01). In multivariate analysis accounting for risk factors associated for HCQ eye toxicity, the presence of anti‐arrestin antibodies was associated with a 3.2‐fold increase in the odds of developing HCQ eye toxicity. Conclusion Anti‐retinal AAbs were more common in patients with SLE with HCQ retinal toxicity. When controlling for risk factors associated with HCQ toxicity, anti‐arrestin AAbs were associated with increased odds for the development of eye toxicity, suggesting a potential role for anti‐retinal AAbs as a biomarker of HCQ eye toxicity. |
| format | Article |
| id | doaj-art-ed3b15b25c474d00ae0853928bd3838b |
| institution | Kabale University |
| issn | 2578-5745 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | ACR Open Rheumatology |
| spelling | doaj-art-ed3b15b25c474d00ae0853928bd3838b2025-02-04T06:21:23ZengWileyACR Open Rheumatology2578-57452025-01-0171n/an/a10.1002/acr2.11743Anti‐retinal Autoantibodies in Hydroxychloroquine Eye ToxicitySamuel D. Good0Grazyna Adamus1Michael B. Gorin2Jordan Jacquez3Jennifer Grossman4Isao Matsuura5Ashira Hasan6Brian Skaggs7Maureen McMahon8David Geffen School of Medicine Division of Rheumatology University of California Los Angeles Los Angeles USACasey Eye Institute Oregon Health & Science University Portland USARetinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, David Geffen School of Medicine University of California Los Angeles Los AngelesDavid Geffen School of Medicine Division of Rheumatology University of California Los Angeles Los Angeles USADavid Geffen School of Medicine Division of Rheumatology University of California Los Angeles Los Angeles USADepartment of Allergy and Clinical Immunology Asahi General Hospital Chiba JapanCasey Eye Institute Oregon Health & Science University Portland USADavid Geffen School of Medicine Division of Rheumatology University of California Los Angeles Los Angeles USADavid Geffen School of Medicine Division of Rheumatology University of California Los Angeles Los Angeles USAObjective Autoimmune retinopathy and hydroxychloroquine (HCQ)‐related retinal toxicity share many similarities, raising the possibility autoimmunity plays a role in HCQ retinopathy. The objective of this study is to determine whether patients diagnosed with HCQ retinal toxicity are more likely to have circulating antiretinal autoantibodies (AAbs) compared to controls. Methods We tested plasma samples for the presence of anti‐retinal AAbs by immunoblotting in 270 patients with systemic lupus erythematosus (SLE) receiving HCQ. We then evaluated for the presence of HCQ retinal toxicity and other baseline risk factors for HCQ toxicity through chart review. Frequency of specific anti‐retinal AAbs in patients with HCQ retinal toxicity was compared to those with no retinal toxicity via multivariate logistic regression. Results Patients with HCQ retinal toxicity had a higher likelihood of testing positive for anti‐arrestin AAbs (60.7% vs 30.6%, P = 0.001) and anti–pyruvate kinase M2 AAbs (46.4% vs 28.1%, P = 0.05). Patients with HCQ eye toxicity also had a higher number of total anti‐retinal AAbs (mean 3.0 ± 2.40 vs 2.04 ± 1.7, P = 0.01). In multivariate analysis accounting for risk factors associated for HCQ eye toxicity, the presence of anti‐arrestin antibodies was associated with a 3.2‐fold increase in the odds of developing HCQ eye toxicity. Conclusion Anti‐retinal AAbs were more common in patients with SLE with HCQ retinal toxicity. When controlling for risk factors associated with HCQ toxicity, anti‐arrestin AAbs were associated with increased odds for the development of eye toxicity, suggesting a potential role for anti‐retinal AAbs as a biomarker of HCQ eye toxicity.https://doi.org/10.1002/acr2.11743 |
| spellingShingle | Samuel D. Good Grazyna Adamus Michael B. Gorin Jordan Jacquez Jennifer Grossman Isao Matsuura Ashira Hasan Brian Skaggs Maureen McMahon Anti‐retinal Autoantibodies in Hydroxychloroquine Eye Toxicity ACR Open Rheumatology |
| title | Anti‐retinal Autoantibodies in Hydroxychloroquine Eye Toxicity |
| title_full | Anti‐retinal Autoantibodies in Hydroxychloroquine Eye Toxicity |
| title_fullStr | Anti‐retinal Autoantibodies in Hydroxychloroquine Eye Toxicity |
| title_full_unstemmed | Anti‐retinal Autoantibodies in Hydroxychloroquine Eye Toxicity |
| title_short | Anti‐retinal Autoantibodies in Hydroxychloroquine Eye Toxicity |
| title_sort | anti retinal autoantibodies in hydroxychloroquine eye toxicity |
| url | https://doi.org/10.1002/acr2.11743 |
| work_keys_str_mv | AT samueldgood antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT grazynaadamus antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT michaelbgorin antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT jordanjacquez antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT jennifergrossman antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT isaomatsuura antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT ashirahasan antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT brianskaggs antiretinalautoantibodiesinhydroxychloroquineeyetoxicity AT maureenmcmahon antiretinalautoantibodiesinhydroxychloroquineeyetoxicity |